DCBOApril 30, 2026 at 7:11 AM UTCSoftware & Services

Docebo Raises FY26 Guidance but Land-and-Expand Remains Unproven

Read source article

What happened

Docebo reported modest FY25 ARR growth of 8.4% and a net dollar retention (NDR) of 99%, indicating that its land-and-expand strategy has yet to gain traction despite a strategic shift toward larger enterprise clients. Management raised FY26 guidance for revenue and adjusted EBITDA, citing resolution of AWS churn and wind-down of Dayforce operations as improving business optics. The company is expanding into skills intelligence via the 365Talents acquisition and enhancing retention per client, but the underlying growth metrics remain below what would confirm a durable upsell model. The bullish thesis from the DeepValue Master Report, which emphasized profitable growth, AI-native features, and FedRAMP opportunity, now faces a more cautious near-term reality where organic growth is slowing. The raised guidance provides some optimism, but without evidence of accelerating ARR or improving NDR, the investment case hinges on future execution rather than current momentum.

Implication

The core thesis—Docebo as a differentiated, AI-first LMS with public-sector optionality—remains intact, but the latest data shows that the land-and-expand engine is not firing. Investors should monitor upcoming quarters for ARR growth acceleration to mid-teens and NDR above 100% as evidence of a turnaround. The raised FY26 guidance provides a near-term floor, but without organic momentum, the stock may trade sideways. A disciplined approach is to hold existing positions and add only on clear improvement in NRR and ARR trajectory. Risks include slower enterprise adoption, HCM suite competition, and failure to monetize AI modules.

Thesis delta

The DeepValue Master Report rated Docebo a BUY based on profitable growth and optionality from AI and FedRAMP. The new data showing only 8.4% ARR growth and 99% NDR in FY25 indicates that the expected acceleration from land-and-expand has not materialized. This tempers the bullish outlook: the thesis shifts from 'BUY on future potential' to 'HOLD until organic growth re-accelerates.' The raised FY26 guidance is encouraging but insufficient to confirm a durable growth re-rate. The watch items from the master report (ARR/NRR, AI monetization, public-sector wins) now carry greater weight, and the thesis delta is a move toward caution—the company must prove it can grow faster before the multiple can expand.

Confidence

Medium